13F Holdings
中文EN

BDMD Baird Medical Investment Holdings Ltd Annual reports only

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1982444 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-39.2%
TTM net income YoY-319.0%
TTM EPS YoY-271.9%
Revenue 3-yr CAGR-13.7%
Net income 3-yr CAGR—

Margins

Gross margin83.8%
Operating margin-113.7%
Net margin-121.0%
FCF margin-6.2%
EBITDA margin-108.8%

Returns

ROE-76.8%
ROA-36.9%
ROIC (approx.)-50.1%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets55.2%
Debt / equity0.28x
Current ratio1.70x
Interest coverage-72.33x

Cash quality & payout

Operating cash flow / net income0.05x
Accruals ratio-35.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31
Income statement
Revenue$22.54M$37.04M$31.46M$35.09M
Cost of revenue$3.65M$4.38M$4.23M$7.05M
Gross profit$18.88M$32.65M$27.23M$28.04M
R&D expense$20.13M$6.17M$4.27M$3.86M
SG&A expense$14.12M$7.10M$8.55M$6.96M
Operating income-$25.63M$15.32M$11.86M$13.63M
Interest expense$354,341$388,613$227,923$299,269
Pretax income-$26.37M$14.09M$12.36M$14.52M
Income tax$1.17M$1.49M$1.70M$1.75M
Net income-$27.28M$12.45M$10.55M$12.57M
EBITDA-$24.53M$16.45M$12.88M$14.55M
EPS (basic)-0.980.570.510.49
EPS (diluted)-0.980.570.510.49
Weighted avg. shares (diluted)27.79M21.83M20.59M25.56M
Balance sheet
Cash & equivalents$178,321$2.97M$1.51M$1.71M
Receivables$42.53M$46.58M$31.10M—
Inventory$1.09M$1.30M$1.14M—
Current assets$54.97M$61.42M$40.08M—
PP&E, net$6.37M$7.14M$6.14M—
Goodwill$60,303$57,772$59,375—
Intangibles$8,626$16,528$25,479—
Total assets$69.70M$77.96M$56.71M—
Current liabilities$32.36M$34.62M$18.98M—
Short-term debt$2.64M$867,772$817,485—
Long-term debt$6.09M$3.44M$1.61M—
Total debt$8.72M$4.31M$2.43M—
Total liabilities$38.48M$38.20M$21.00M—
Shareholders' equity$31.37M$39.66M$35.75M$25.78M
Net debt$8.54M$1.34M$920,580—
Shares outstanding30.75M25.56M29.41M—
Cash flow statement
Operating cash flow-$1.34M-$6.31M-$1.02M$485,968
Capital expenditure$42,315$2.85M$2.64M$5.91M
Free cash flow-$1.39M-$9.17M-$3.66M-$5.42M
Investing cash flow-$42,315-$2.47M-$2.65M-$5.92M
Financing cash flow-$1.39M$10.33M$3.48M$4.41M
Depreciation & amortization$1.10M$1.14M$1.01M$916,115
Stock-based compensation$17.47M$0$0—

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.